Drug Approval | December 28, 2021
Strides to market molnupiravir under the brand name Stripiravir
Molnupiravir is an orally administered form of a potent ribonucleoside analog that inhibits the replication of SARS-CoV-2
Molnupiravir is an orally administered form of a potent ribonucleoside analog that inhibits the replication of SARS-CoV-2
The company will market it under the brand name Molflu
It is indicated for the treatment of patients with acromegaly and Gastroenteropancreatic Neuroendocrine Tumours
The investment will establish additional capacity across the entire global value chain from manufacturing of active pharmaceutical ingredients (API) to assembly and packaging, with the vast majority being invested in API capacity
KOREA PACK and concurrent event ICPI Week (Int’l Cosmetic and Pharmaceutical Industry Week) will be held as hybrid events in 2022
Approvals accorded under Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical Key Starting Materials (KSMs)/ drug intermediates and Active Pharmaceutical Ingredients (APIs
Healtherbs helps in restoring the desired energy levels for daily activity and immunity
The appraisal of the applications has been carried out based on the ranking methodology laid down in the operational guidelines of the Scheme
The nutraceutical sector is on the cusp of exponential growth and Covid-19 has accelerated the pace of its applications. Dr R.B Smarta, CMD, Interlink, shares his perspective on the growth opportunities and challenges for the sector
A CRISIL study of 207 pharmaceutical companies that account for 55% of the Rs 3.2 lakh crore-a-year sector revenue indicates as much.
Subscribe To Our Newsletter & Stay Updated
